Clinically Reviewed by Melissa Lemeteyer, NP
If you only know GLP-1 medications from headlines, Instagram, or celebrity before-and-after photos, you might think their primary purpose is to make people lose weight.
But that’s not actually where these medications started.
GLP-1 medications were originally developed to treat type 2 diabetes, and researchers have since found that their effects extend well beyond the number on the scale. Depending on the medication and the person taking it, GLP-1s can improve blood sugar, lower cardiovascular risk, protect kidney function, treat certain forms of liver disease, and potentially affect everything from inflammation to alcohol cravings.
That matters because not everyone taking a GLP-1 does so with weight loss as a goal.
Someone might be interested in improving their A1C, managing insulin resistance, reducing their risk of heart or kidney disease, or treating another health condition while feeling perfectly comfortable at their current size. For some people, weight loss may even be an unwanted side effect.
So what can GLP-1 medications actually do besides change your weight?
First: What Are GLP-1 Medications?
GLP-1 stands for glucagon-like peptide-1, a hormone your body naturally produces after you eat. It helps regulate blood sugar, insulin secretion, digestion, appetite, and communication between your gut and brain.
Medications including semaglutide (Ozempic and Wegovy) and liraglutide (Victoza and Saxenda) mimic GLP-1 activity. Tirzepatide (Mounjaro and Zepbound) works on both GLP-1 and another hormone pathway called GIP, so you may hear it described as a dual GIP/GLP-1 medication.
Different medications have different FDA-approved uses, and a benefit shown with one GLP-1 medication shouldn’t automatically be assumed to apply equally to every drug in the class.
1. Better Blood Sugar Control
Long before GLP-1s became famous for weight loss, they were diabetes medications.
GLP-1 medications help your pancreas release insulin when blood sugar is elevated. They can also decrease glucagon, a hormone that tells your liver to release stored glucose.
Together, those effects can lower fasting and after-meal blood sugar and reduce A1C in people with type 2 diabetes. Ozempic, for example, is FDA-approved specifically to improve glycemic control in adults with type 2 diabetes.
And importantly, blood sugar improvement is a treatment outcome in its own right. A person does not have to view weight loss as the goal of diabetes treatment.
2. Protection Against Heart Attack and Stroke
Some GLP-1 medications have demonstrated cardiovascular benefits that go far beyond changing someone's appearance or BMI.
Ozempic is approved to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Wegovy is also FDA-approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who meet its weight-related eligibility criteria.
That distinction is important.
The outcome researchers care about here isn't simply whether someone weighs less. It's whether they are less likely to experience a heart attack, stroke, or cardiovascular death.
Weight loss may contribute to some of these improvements, along with changes in blood pressure, glucose regulation, inflammation, and other metabolic pathways. Researchers are still studying exactly how much each mechanism contributes.
3. Kidney Protection
One of the biggest developments in GLP-1 research has been evidence that semaglutide can help protect kidney function in certain people with type 2 diabetes.
In 2025, the FDA expanded Ozempic's indication to include reducing the risk of sustained decline in kidney function, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.
The approval followed the large FLOW trial, in which semaglutide reduced the risk of major kidney-related outcomes among people with both type 2 diabetes and chronic kidney disease.
For someone taking a GLP-1 primarily because they're trying to protect their kidneys, the scale may be one of the least interesting measures of whether treatment is working.
4. Treatment for Certain Types of Fatty Liver Disease
GLP-1 medications have also moved into liver care.
In 2025, the FDA approved Wegovy to treat adults with metabolic dysfunction-associated steatohepatitis, or MASH, with moderate-to-advanced liver fibrosis. MASH is a progressive form of fatty liver disease in which fat accumulation is accompanied by inflammation and liver scarring.
In the clinical trial supporting the approval, people taking semaglutide were more likely than those taking placebo to experience resolution of MASH without worsening fibrosis, as well as improvement in liver fibrosis without worsening MASH.
Again, weight may change during treatment—but the clinical target here is what is happening inside the liver.
5. Improvements in Cardiometabolic Health
GLP-1 medications can affect several markers associated with metabolic and cardiovascular health, including blood pressure, blood sugar, and in some studies markers of inflammation.
For example, trials studying semaglutide in people with obesity-related heart failure with preserved ejection fraction, or HFpEF, found improvements in heart-failure symptoms, physical limitations, exercise capacity, and levels of C-reactive protein, a marker associated with inflammation.
That doesn't necessarily mean those effects are completely independent of weight loss. In many GLP-1 trials, participants lose weight at the same time, making it difficult to separate every biological pathway involved.
But it does mean that weight is only one outcome researchers are measuring.
6. PMOS and Insulin Resistance: Promising, but Still Emerging
GLP-1 medications are also being studied for polyendocrine metabolic ovarian syndrome (PMOS), formerly known as polycystic ovary syndrome (PCOS), particularly when insulin resistance or other metabolic concerns are involved.
Because GLP-1s improve insulin signaling and glucose regulation, researchers have investigated whether they could help with some of the metabolic and hormonal features of PCOS.
So far, the evidence is promising but mixed. Recent systematic reviews have found improvements in some metabolic measures, but evidence for outcomes such as menstrual regularity, hormone levels, and other PCOS symptoms is still limited or inconsistent.
GLP-1 medications are not currently FDA-approved specifically for PMOS, so this remains an evolving area of care rather than an established indication.
7. Reduced Alcohol Cravings and Other Reward-Seeking Behaviors
This is one of the more intriguing areas of GLP-1 research.
GLP-1 receptors aren't found only in the digestive system. They also interact with areas of the brain involved in reward and motivation, which has led researchers to investigate whether these medications might influence cravings for alcohol, nicotine, or other substances.
In a small randomized clinical trial published in 2025, low-dose semaglutide reduced several measures of alcohol consumption and craving among adults with alcohol use disorder.
That's exciting—but very preliminary.
Semaglutide is not FDA-approved to treat alcohol use disorder, and we need much larger studies before knowing exactly where GLP-1 medications might fit into addiction treatment.
Still, it helps illustrate something important: these medications affect multiple systems throughout the body and brain. Appetite is only one of them.
What About Inflammation, Autoimmune Conditions, and Pain?
This is one of the most interesting—and still developing—areas of GLP-1 research.
GLP-1 medications appear to do more than regulate appetite and blood sugar. Laboratory and animal studies suggest that GLP-1 signaling can influence immune cells and inflammatory pathways, including some of the cytokines involved in autoimmune and inflammatory diseases.
Researchers are now studying whether that could translate into meaningful benefits for conditions including rheumatoid arthritis, psoriatic arthritis, psoriasis, inflammatory bowel disease, hidradenitis suppurativa, and other immune-mediated diseases.
There are some encouraging early findings. Recent research in people with arthritis has linked GLP-1 use with improvements in pain, physical function, and—in some studies—lower inflammatory disease activity. Experimental evidence also suggests GLP-1 medications may have anti-inflammatory and cartilage-protective effects that aren't entirely explained by weight loss.
But this is still an emerging area of medicine.
GLP-1 medications are not currently approved as treatments for rheumatoid arthritis, lupus, fibromyalgia, or chronic pain in general, and the quality of evidence varies substantially depending on the condition. For many autoimmune diseases, we still have observational studies, small trials, or laboratory evidence rather than the large randomized trials needed to establish a treatment.
Could GLP-1s reduce pain?
Possibly—but “pain” is especially complicated.
In osteoarthritis, clinical studies have found improvements in pain and physical function among people taking GLP-1 medications. Researchers are investigating whether this comes entirely from reduced mechanical stress on joints or whether GLP-1s also directly affect inflammation, cartilage, or pain signaling.
For inflammatory arthritis, there are also early signals of reduced joint symptoms and disease activity.
That doesn't mean a GLP-1 should currently be thought of as a pain medication. But if someone tells their healthcare provider, “My joints hurt less since I started this,” that's not necessarily an implausible or purely weight-related observation.
What if I have an autoimmune condition?
Having an autoimmune condition does not automatically mean that a GLP-1 will improve it—or that a GLP-1 is appropriate for you.
The most established treatments for autoimmune diseases still target those diseases specifically. GLP-1s shouldn't replace medications such as biologics or other immune-modifying treatments without guidance from the clinician managing your condition.
But researchers are paying close attention to the immune effects of these drugs, and this may eventually become a much bigger part of the GLP-1 story.
Does “Benefits Beyond Weight Loss” Mean the Benefits Have Nothing to Do With Weight?
Not necessarily.
This is an important distinction.
When we talk about benefits beyond weight loss, we mean health outcomes other than losing weight. We don't necessarily mean that scientists have proven those outcomes occur completely independently of weight change.
Losing body fat can itself affect blood pressure, blood sugar, sleep apnea, liver fat, inflammation, and cardiovascular risk. At the same time, GLP-1 medications also act directly on receptors throughout the pancreas, brain, gastrointestinal system, cardiovascular system, and other tissues.
Researchers are still working to untangle how much of each benefit comes from weight change versus other effects of the medication.
You don't have to solve that scientific question before deciding what your treatment goal is.
What If I Want the Health Benefits but Don't Want to Lose Weight?
Tell your healthcare provider.
Seriously.
Weight loss is so culturally baked into the conversation around GLP-1s that people sometimes assume they're supposed to be excited about it. You don't have to be.
You might say that your goal is:
- lowering your A1C
- managing diabetes or insulin resistance
- protecting your cardiovascular health
- reducing kidney disease risk
- treating another diagnosed metabolic condition
- improving specific lab values
- or simply feeling better without intentionally changing your body size
Your provider can help determine whether a GLP-1 medication makes sense for that goal.
That said, there currently isn't a way to turn on the other effects of a GLP-1 while guaranteeing that weight loss won't happen. Decreased appetite, earlier fullness, and weight loss are common effects of many of these medications.
If maintaining your current weight is important to you—or if weight loss could be physically or emotionally harmful—your provider should know that before you start. That may affect medication choice, dosing, nutrition planning, monitoring, or whether a GLP-1 is the right treatment for you at all.
This can be especially important for people with a current or previous eating disorder, people who already struggle to eat enough, and anyone for whom intentional weight loss simply isn't a healthcare goal.
Your Weight Doesn't Have to Be the Scorecard
The enormous cultural attention around GLP-1s has made it easy to forget that a medication can be working even when its most visible effect isn't the effect you care about.
A lower A1C matters.
Better kidney function matters.
Reducing cardiovascular risk matters.
Improving liver disease matters.
Being able to move through your life with fewer symptoms matters.
And if you and your healthcare provider decide that a GLP-1 medication might help you reach one of those goals, you don't have to make weight loss the measure of success.
